We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

228 hedge funds and large institutions have $3.76B invested in Medicines Co in 2019 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 91 increasing their positions, 57 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 25

60% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 57

34% more capital invested

Capital invested by funds: $2.8B → $3.76B (+$958M)

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

12% more funds holding

Funds holding: 203228 (+25)

30% less call options, than puts

Call options by funds: $224M | Put options by funds: $320M

Holders
228
Holders Change
+25
Holders Change %
+12.32%
% of All Funds
4.95%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.17%
New
52
Increased
91
Reduced
57
Closed
25
Calls
$224M
Puts
$320M
Net Calls
-$95.3M
Net Calls Change
-$70.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Invesco
26
Invesco
Georgia
$26.8M +$5.3M +162,299 +28%
GC
27
Greenlight Capital
New York
$26.7M -$7.09M -217,200 -23%
JP Morgan Chase
28
JP Morgan Chase
New York
$25M +$526K +16,112 +2%
VC
29
Vivo Capital
California
$24.4M +$21.8M +669,012 New
Deutsche Bank
30
Deutsche Bank
Germany
$24.3M +$12.3M +378,126 +131%
PAM
31
Panagora Asset Management
Massachusetts
$21.4M +$4.26M +130,607 +29%
Principal Financial Group
32
Principal Financial Group
Iowa
$21M +$1.22M +37,439 +7%
Norges Bank
33
Norges Bank
Norway
$21M +$4.75M +145,398 +34%
PA
34
Pinnacle Associates
New York
$20.4M -$4.91M -150,492 -21%
Citadel Advisors
35
Citadel Advisors
Florida
$20.2M +$5.44M +166,559 +43%
LPC
36
Lion Point Capital
New York
$18.3M +$11.4M +350,700 +234%
First Eagle Investment Management
37
First Eagle Investment Management
New York
$17.4M -$473K -14,500 -3%
N
38
Nuveen
North Carolina
$16.5M +$14.8M +453,697 New
GIM
39
Granahan Investment Management
Massachusetts
$16M -$1.94M -59,421 -12%
Charles Schwab
40
Charles Schwab
California
$14.4M +$366K +11,207 +3%
BNP Paribas Asset Management
41
BNP Paribas Asset Management
France
$14M +$12.6M +384,642 New
ECP
42
Elk Creek Partners
Colorado
$13.7M -$12.6M -385,826 -51%
USAA
43
United Services Automobile Association
Texas
$13M -$377K -11,550 -3%
Renaissance Technologies
44
Renaissance Technologies
New York
$12.9M +$11.5M +353,432 New
EAM
45
Eventide Asset Management
Massachusetts
$12.2M
Morgan Stanley
46
Morgan Stanley
New York
$12.1M +$9.21M +282,029 +562%
Parallax Volatility Advisers
47
Parallax Volatility Advisers
California
$11.5M -$2.39M -73,135 -19%
AAMU
48
Amundi Asset Management US
Massachusetts
$11.4M +$10M +306,195 +5,020%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$11.1M +$61.1K +1,871 +0.6%
UBS AM
50
UBS AM
Illinois
$10.2M -$272K -8,328 -3%

MDCO Hedge Fund Activity: Q2 2019 in Review

228 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q2 2019, worth a combined $3.76B — up 34% from $2.8B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new MDCO positions and 25 closed out — a net gain of 27 holders — while 91 added to existing stakes and 57 trimmed.

The largest buyer was State Street, adding an estimated $46.7M. The largest seller was Aviva Holdings, cutting an estimated $91.3M.

  • 228 institutional investors held Medicines Co (MDCO) as of Q2 2019, up from 203 in Q1 2019.
  • Funds reported $3.76B of Medicines Co stock for Q2 2019, up 34% quarter-over-quarter.
  • 52 funds opened new Medicines Co positions in Q2 2019 and 25 closed out, a net change of +27 holders.
  • The largest Medicines Co buyer in Q2 2019 was State Street, an estimated $46.7M added.
  • The largest Medicines Co seller in Q2 2019 was Aviva Holdings, an estimated $91.3M sold.

Based on aggregated 13F filings for Q2 2019.